201 related articles for article (PubMed ID: 2010630)
1. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.
Baumgartner JD; Heumann D; Calandra T; Glauser MP
J Infect Dis; 1991 Apr; 163(4):769-72. PubMed ID: 2010630
[TBL] [Abstract][Full Text] [Related]
2. Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111:B4.
Schwartzer TA; Alcid DV; Numsuwan V; Gocke DJ
J Infect Dis; 1989 Jan; 159(1):35-42. PubMed ID: 2462603
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to core lipopolysaccharide determinants: absence of cross-reactivity with heterologous lipopolysaccharides.
Heumann D; Baumgartner JD; Jacot-Guillarmod H; Glauser MP
J Infect Dis; 1991 Apr; 163(4):762-8. PubMed ID: 1707084
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides.
Aydintug MK; Inzana TJ; Letonja T; Davis WC; Corbeil LB
J Infect Dis; 1989 Nov; 160(5):846-57. PubMed ID: 2681436
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria.
Siber GR; Kania SA; Warren HS
J Infect Dis; 1985 Nov; 152(5):954-64. PubMed ID: 2413146
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.
Baumgartner JD; O'Brien TX; Kirkland TN; Glauser MP; Ziegler EJ
J Infect Dis; 1987 Jul; 156(1):136-43. PubMed ID: 2439613
[TBL] [Abstract][Full Text] [Related]
7. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.
Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS
J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067
[TBL] [Abstract][Full Text] [Related]
8. Shielding Effect of Escherichia coli O-Antigen Polysaccharide on J5-Induced Cross-Reactive Antibodies.
Rainard P; Repérant-Ferter M; Gitton C; Germon P
mSphere; 2021 Jan; 6(1):. PubMed ID: 33504665
[No Abstract] [Full Text] [Related]
9. Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins.
Appelmelk BJ; Maaskant JJ; Verweij-van Vught AM; van der Meer NM; Thijs BG; MacLaren DM
J Gen Microbiol; 1993 Nov; 139(11):2641-7. PubMed ID: 7506295
[TBL] [Abstract][Full Text] [Related]
10. Hyperimmunization of steers with J5 Escherichia coli bacterin: effects on isotype-specific serum antibody responses and cross reactivity with heterogeneous gram-negative bacteria.
Chaiyotwittayakun A; Burton JL; Weber PS; Kizilkaya K; Cardoso FF; Erskine RJ
J Dairy Sci; 2004 Oct; 87(10):3375-85. PubMed ID: 15377616
[TBL] [Abstract][Full Text] [Related]
11. Antigenic homology of endotoxin with a coliform mastitis vaccine strain, Escherichia coli O111:B4 (J5).
Tyler JW; Spears H; Nelson R
J Dairy Sci; 1992 Jul; 75(7):1821-5. PubMed ID: 1500577
[TBL] [Abstract][Full Text] [Related]
12. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.
Marks MI; Ziegler EJ; Douglas H; Corbeil LB; Braude AI
J Clin Invest; 1982 Apr; 69(4):742-9. PubMed ID: 7042755
[TBL] [Abstract][Full Text] [Related]
13. Role of magnesium in the enzyme-linked immunosorbent assay for lipopolysaccharides of rough Escherichia coli strain J5 and Neisseria gonorrhoeae.
Ito JI; Wunderlich AC; Lyons J; Davis CE; Guiney DG; Braude AI
J Infect Dis; 1980 Oct; 142(4):532-7. PubMed ID: 6777436
[TBL] [Abstract][Full Text] [Related]
14. Antibody specific for Escherichia coli J5 cross-reacts to various degrees with an Escherichia coli clinical isolate grown for different lengths of time.
McCallus DE; Norcross NL
Infect Immun; 1987 May; 55(5):1042-6. PubMed ID: 3552983
[TBL] [Abstract][Full Text] [Related]
15. Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.
de Jongh-Leuvenink J; Schellekens J; Verhoef J
Infect Immun; 1990 Feb; 58(2):421-6. PubMed ID: 2404871
[TBL] [Abstract][Full Text] [Related]
16. Enzyme immunoassay for the quantitation of immunoglobulin M class antibodies to Salmonella minnesota R595 and Escherichia coli J5 lipopolysaccharides.
Vanesian MA; Fung G; Bagdasarian A
Diagn Microbiol Infect Dis; 1987 Jan; 6(1):11-25. PubMed ID: 3542358
[TBL] [Abstract][Full Text] [Related]
17. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.
Bhattacharjee AK; Opal SM; Palardy JE; Drabick JJ; Collins H; Taylor R; Cotton A; Cross AS
J Infect Dis; 1994 Sep; 170(3):622-9. PubMed ID: 8077720
[TBL] [Abstract][Full Text] [Related]
18. Administration in vivo of recombinant interleukin 2 protects mice against septic death.
Weyand C; Goronzy J; Fathman CG; O'Hanley P
J Clin Invest; 1987 Jun; 79(6):1756-63. PubMed ID: 3294901
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in protection provided by immunization against core lipopolysaccharides of Escherichia coli J5 from lethal Haemophilus pleuropneumoniae infections in swine.
Fenwick BW; Cullor JS; Osburn BI; Olander HJ
Infect Immun; 1986 Aug; 53(2):298-304. PubMed ID: 3525407
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of polyclonal sera and of monoclonal antibodies active to Salmonella minnesota Re595 lipopolysaccharide during experimental endotoxemia.
Nys M; Cloes JM; Demonty J; Joassin L
J Infect Dis; 1990 Nov; 162(5):1087-95. PubMed ID: 1700024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
